Pharmacogenomics represents the intersection of pharmacology and genomics, offering the promise of personalized medicine by tailoring drug therapy to an individual's genetic makeup. For patients with Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP), this approach is particularly relevant given the complex medication regimens required to manage motor, cognitive, and psychiatric symptoms.
The aging brain and the neurodegenerative disease state present unique pharmacokinetic and pharmacodynamic challenges. Genetic variations in drug-metabolizing enzymes, drug targets, and transporters can significantly alter medication efficacy and toxicity. This section provides a comprehensive overview of pharmacogenomic testing relevant to CBS/PSP, including CYP450 genotyping, gene-drug interactions, clinical implementation strategies, and decision frameworks for integrating pharmacogenomics into clinical practice.
Individual variability in drug response stems from genetic polymorphisms in genes encoding:
- Cytochrome P450 enzymes (CYP family): Primary drug metabolism
- Phase II conjugation enzymes: UGT, SULT, NAT
- Drug transporters: ABC and SLC family members
- Drug targets: Receptors, enzymes, ion channels
In CBS/PSP patients, these genetic variations can affect:
- Levodopa metabolism — affects motor response fluctuations
- Antidepressant efficacy and side effects — common for depression management
- Benzodiazepine sensitivity — used for anxiety and sleep
- Analgesic response — for pain management
- Cholinesterase inhibitor tolerance — for cognitive symptoms
The typical CBS/PSP patient is often on multiple medications targeting different symptom domains:
| Medication Class |
Common Drugs |
Key Gene |
Clinical Impact |
| Dopaminergic |
Levodopa/Carbidopa |
COMT, DBH, DRD2 |
Motor fluctuations |
| Antidepressants |
SSRIs, SNRIs |
CYP2D6, CYP2C19 |
Efficacy/SERS |
| Benzodiazepines |
Clonazepam, Lorazepam |
CYP3A4 |
Sedation, dependence |
| Analgesics |
Tramadol, Oxycodone |
CYP2D6, CYP3A4 |
Efficacy, toxicity |
| Anticholinergics |
Trihexyphenidyl |
CYP1A2 |
CNS side effects |
¶ 2. Cytochrome P450 System and CBS/PSP Medications
CYP2D6 metabolizes approximately 25% of all drugs, including many used in movement disorders.
| Phenotype |
Enzyme Activity |
Clinical Implications |
| Poor Metabolizer (PM) |
Minimal activity |
Higher drug levels, increased toxicity risk |
| Intermediate Metabolizer (IM) |
Reduced activity |
Variable response, may need dose adjustment |
| Normal Metabolizer (NM) |
Normal activity |
Standard dosing |
| Ultrarapid Metabolizer (UM) |
Enhanced activity |
Lower drug levels, potential treatment failure |
Substrates include:
- Beta-blockers (metoprolol, carvedilol)
- Tricyclic antidepressants (amitriptyline, nortriptyline)
- SSRIs (fluoxetine, paroxetine — strong inhibitors)
- Opioids (codeine, tramadol, oxycodone)
- Antiemetics (ondansetron)
Clinical Implications:
- PMs may experience excessive sedation with normal doses
- UMs may require higher doses for therapeutic effect
- Drug-drug interactions are particularly important in PMs
CYP2C19 plays a critical role in metabolizing several antidepressants commonly used in CBS/PSP.
CYP2C19 Substrates:
- Antidepressants: Escitalopram, citalopram, sertraline (minor)
- Proton pump inhibitors: Omeprazole (may affect absorption)
- Clopidogrel: Requires activation (relevant for cardiovascular comorbidity)
CYP2C19 Inhibitors:
- Fluconazole, fluvoxamine
- Omeprazole, esomeprazole
Clinical Consideration:
- CYP2C19 PMs may have increased escitalopram/citalopram exposure
- Consider alternative antidepressants (e.g., sertraline) in PMs
CYP3A4 metabolizes the majority of drugs used in clinical practice. CYP3A4 is particularly important for CBS/PSP patients given its role in metabolizing many commonly prescribed medications.
| Drug Class |
Example |
Interaction Risk |
| Benzodiazepines |
Clonazepam, alprazolam |
High with inhibitors |
| Calcium channel blockers |
Amlodipine |
May affect BP management |
| Statins |
Atorvastatin, simvastatin |
Myopathy risk |
| Immunosuppressants |
N/A |
Not commonly used |
¶ Important Inhibitors and Inducers
Strong Inhibitors:
- Ketoconazole, itraconazole
- Clarithromycin, erythromycin
- Grapefruit juice
Inducers:
- Carbamazepine, phenytoin
- Rifampin
- St. John's Wort
¶ 2.4 COMT and Levodopa Response
While not a CYP enzyme, Catechol-O-methyltransferase (COMT) is critical for levodopa metabolism.
Val158Met (rs4680):
- Val/Val: Higher COMT activity → faster levodopa metabolism → shorter "on" time
- Met/Met: Lower COMT activity → prolonged levodopa effect → more "on" time
- Met/Val: Intermediate phenotype
Clinical Implications:
- Val/Val patients may benefit from:
- More frequent levodopa dosing
- COMT inhibitor use (entacapone, tolcapone)
- Higher levodopa doses
- Met/Met patients may experience:
- More motor fluctuations
- Higher risk of dyskinesias
- May benefit from lower doses
Rs1799732 (-141C Ins/Del):
- Insertion allele associated with higher DRD2 expression
- May affect levodopa response
- Relevant for dopamine agonist therapy
Rs1800497 (Taq1A, ANKK1):
- Associated with D2 receptor density
- May predict response to dopaminergic therapies
- Also relevant for antipsychotic-induced movement disorders
- May influence dopamine agonist response
- Potential modifier of levodopa-induced dyskinesias
¶ 3.2 Serotonin Pathway and Antidepressant Response
¶ HTR2A and HTR2C Receptor Variants
HTR2A (rs6313, rs6314):
- May affect SSRI/SNRI response
- Relevant for depression management in CBS/PSP
HTR2C (rs3813929):
- Associated with antidepressant-induced weight changes
- May influence mirtazapine use (for appetite/sleep)
5-HTTLPR polymorphism:
- Short allele associated with:
- Poorer SSRI response
- Higher risk of side effects
- Increased anxiety
- May guide antidepressant selection
¶ 3.3 ABC Transporter Genetics and Drug Transport
Rs1045642 (3435C>T):
- T allele associated with reduced P-gp expression
- May increase CNS penetration of substrates
- Relevant for: levodopa, bromocriptine, cabergoline
Clinical Implication:
- T/T genotype may have enhanced drug CNS effects
- May require dose reductions
- Important for drug-drug interaction counseling
| Test Name |
Company |
Genes Tested |
TAT |
| AmpliChip CYP450 |
Roche/Genmark |
CYP2D6, CYP2C19 |
3-5 days |
| GeneSight |
Myriad Genetics |
12 genes, 45 medications |
2-3 days |
| PharmaGx |
SureRx |
CYP2D6, CYP2C19, CYP3A5 |
5-7 days |
| RxSight |
Coriell |
Multiple panels |
7-10 days |
- 23andMe (limited pharmacogenomics)
- AncestryDNA (limited)
- Specialized pharmacogenomic panels require physician order
Core Panel (Minimum):
- CYP2D6 — affects multiple drug classes
- CYP2C19 — antidepressant metabolism
- CYP3A5 — for patients of African descent (affects many drugs)
Extended Panel (Comprehensive):
- All CYP450 genes relevant to patient's medication list
- COMT for levodopa optimization
- DRD2/DRD3 if available
- ABCB1 for transport optimization
- UGT1A1 for irinotecan (if used for cancer)
Clinical Databases:
- PharmGKB (pharmgkb.org): Comprehensive pharmacogenomics knowledgebase
- CPIC Guidelines (cpicpgx.org): Evidence-based prescribing guidelines
- Clinical Pharmacogenetics Implementation Consortium guidelines for:
- CYP2D6 and codeine/tramadol
- CYP2C19 and clopidogrel/antidepressants
- CYP3A5 and tacrolimus
Indications for Testing:
| Clinical Scenario |
Rationale |
| Inadequate response to standard doses |
May indicate UM or PM status |
| Unexpected toxicity at low doses |
May indicate PM status |
| Multiple drug interactions |
Complex metabolizer profile |
| Planning complex medication regimen |
Pre-emptive testing |
| Poor antidepressant response |
Guide selection |
| Levodopa response fluctuations |
COMT optimization |
flowchart TD
A["Patient on multiple medications"] --> B{"Adverse events or poor response?"}
B -->|"Yes"| C["Consider pharmacogenomic testing"]
B -->|"No"| D["Continue standard therapy"]
C --> E["Select appropriate panel"]
E --> F["Interpret results"]
F --> G{"Actionable finding?"}
G -->|"Yes"| H["Adjust medication/dose"]
G -->|"No"| I["Continue current regimen"]
H --> J["Monitor and reassess"]
I --> J
Step 1: Medication Review
- List all current medications
- Identify drugs with known pharmacogenomic implications
- Assess clinical response and side effects
Step 2: Test Selection
- Match medication needs to test panels
- Consider cost and insurance coverage
- Select validated laboratory
Step 3: Results Interpretation
- Use CPIC guidelines for dosing adjustments
- Consult PharmGKB for additional information
- Consider overall clinical picture
Step 4: Implementation
- Communicate findings to patient
- Document in medical record
- Coordinate with pharmacy
- Monitor outcomes
¶ Cost and Insurance
- Medicare covers some pharmacogenomic testing
- Many commercial insurers have coverage policies
- Patient assistance programs available from some laboratories
- Genetic information privacy (GINA protections)
- Incidental findings
- Family implications
- Informed consent requirements
COMT (rs4680) genotyping:
- Guide: Consider testing for COMT inhibitors
- Val/Val: Stronger indication for entacapone
- Met/Met: Monitor for dyskinesias
SLC22A1 (OCT1):
- Reduced function alleles may affect levodopa transport
- May influence absorption
CYP3A4/5 status:
- Affects bromocriptine, cabergoline, pramipexole metabolism
- PMs: Consider dose reduction
- UMs: May need higher doses
| Drug |
Primary CYP |
Key Polymorphisms |
Clinical Action |
| Fluoxetine |
CYP2D6, CYP2C19 |
PM: avoid or reduce dose |
Avoid in PMs |
| Paroxetine |
CYP2D6 |
Strong inhibitor |
Avoid in PMs |
| Sertraline |
Multiple |
Generally well-tolerated |
Consider first-line |
| Escitalopram |
CYP2C19 |
PM: reduce dose 50% |
Monitor in PMs |
| Drug |
Primary CYP |
Notes |
| Venlafaxine |
CYP2D6 |
PM: reduce dose |
| Duloxetine |
CYP2D6, CYP1A2 |
Monitor in PMs |
For CBS/PSP patients starting antidepressants:
- First-line: Sertraline or citalopram (relatively safe across phenotypes)
- If poor response: Consider pharmacogenomic testing to guide switch
CYP3A4 status affects:
- Clonazepam
- Alprazolam
- Diazepam
Clinical Pearls:
- Long-acting benzodiazepines (diazepam) preferred in liver dysfunction
- Short-acting (lorazepam, oxazepam) safer in CYP polymorphism
- Start low, go slow in PMs
¶ Tramadol and Codeine
CYP2D6 Critical:
- PMs: No conversion to active metabolite → treatment failure
- UMs: Rapid conversion → toxicity risk
- Recommendation: Avoid in PMs and UMs; use alternative
CYP3A4 and CYP2D6:
- Affects both parent drug and active metabolite
- PMs: May have reduced analgesia
- UMs: Monitor for sedation
| Drug |
Primary CYP |
Notes |
| Quetiapine |
CYP3A4 |
UMs: higher doses needed |
| Risperidone |
CYP2D6 |
PMs: monitor extrapyramidal symptoms |
| Clozapine |
CYP1A2, CYP3A4 |
Therapeutic drug monitoring available |
Research in Progress:
- Tau-targeted therapies: Genetic predictors of response
- Neuroinflammation modulators: IL-1, TNF-alpha polymorphisms
- Mitochondrial medications: MT-ND variants
| Barrier |
Current Status |
Future Directions |
| Cost |
Decreasing |
Insurance expansion |
| Turnaround time |
3-10 days |
Point-of-care testing |
| Interpretation |
Guidelines available |
AI-assisted interpretation |
| Clinical integration |
EHR limited |
Better integration tools |
Beyond genetics:
- Transcriptomics: Gene expression patterns
- Proteomics: Protein-based biomarkers
- Metabolomics: Metabolic profiles
- Pharmacometabolomics: Combined approach
¶ 8. Summary and Clinical Recommendations
- Pharmacogenomic testing can improve medication outcomes in CBS/PSP by optimizing dosing and reducing adverse events
- CYP2D6 and CYP2C19 are the highest-priority genes to test given their broad medication coverage
- COMT genotyping may help optimize levodopa therapy for patients with motor fluctuations
- Sertraline and citalopram are first-line antidepressants with favorable pharmacogenomic profiles
- Avoid codeine/tramadol in CYP2D6 PMs and UMs
- Document genetic findings in the medical record for future medication decisions